{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:46:14Z","timestamp":1791582374643,"version":"4.3.4"},"reference-count":32,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"ZonMw","award":["848018013"],"award-info":[{"award-number":["848018013"]}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2024,7,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n              Surgical site infections (SSIs) are among the most clinically relevant complications and the use of prophylactic cefazolin is common practice. However, the knowledge about the pharmacological aspects of prophylactic cefazolin in the lower extremities remains limited. In this prospective cohort, a sub-study of the WIFI-2 randomized controlled trial, adults between 18 and 75 years of age who were scheduled for implant removal below the level of the knee and randomized for cefazolin, was included. A maximum of two venous plasma, target-site plasma, and target-site tissue samples were taken during surgery. The primary outcomes were the cefazolin concentrations in venous plasma, target-site plasma, and target-site tissue. A total of 27 patients [median (interquartile range) age, 42 (29\u201359) years; 17 (63%) male] with 138 samples were included in the study. A minimum of 6 weeks follow-up was available for all patients. The mean (SD) venous plasma, target-site plasma, and target-site tissue concentrations were 36 (13) \u00b5g\/mL, 29 (13) \u00b5g\/mL, and 28 (13) \u00b5g\/g, respectively, and the cefazolin concentrations between the different locations of surgery did not differ significantly in both target-site plasma and target-site tissue (\n              <jats:italic>P<\/jats:italic>\n              = 0.822 and\n              <jats:italic>P<\/jats:italic>\n              = 0.840). In conclusion, 2 g of prophylactic cefazolin demonstrates adequacy in maintaining coverage for a duration of at least 80 minutes of surgery below the level of the knee, significantly surpassing the MIC\n              <jats:sub>90<\/jats:sub>\n              required to combat the most prevalent microorganisms. This study represents the first of its kind to assess cefazolin concentrations in the lower extremities by examining both plasma and tissue samples in this magnitude.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1128\/aac.00494-24","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T13:02:15Z","timestamp":1716296535000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":5,"title":["Plasma and tissue concentrations of 2 g prophylactic cefazolin prior to lower extremity surgery"],"prefix":"10.1128","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8836-4738","authenticated-orcid":false,"given":"Robin","family":"Eelsing","sequence":"first","affiliation":[{"name":"Department of Surgery, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands"},{"name":"Amsterdam Movement Sciences, AMS - Musculoskeletal Health, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederick","family":"Penning","sequence":"additional","affiliation":[{"name":"Department of Surgery, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands"},{"name":"Amsterdam Movement Sciences, AMS - Musculoskeletal Health, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marloes","family":"Vos-van der Meer","sequence":"additional","affiliation":[{"name":"Pharmacy laboratory, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0372-0279","authenticated-orcid":false,"given":"Caspar J.","family":"Hodiamont","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron A. A.","family":"Math\u00f4t","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy and Clinical Pharmacology, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1172-4939","authenticated-orcid":false,"given":"Tim","family":"Schepers","sequence":"additional","affiliation":[{"name":"Department of Surgery, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands"},{"name":"Amsterdam Movement Sciences, AMS - Musculoskeletal Health, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00402-015-2219-5"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003086-200110000-00017"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.injury.2022.10.017"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.25270\/wnds\/21098"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.7416\/ai.2017.2174"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00264-013-2181-1"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1302\/0301-620X.99B8.BJJ-2016-1119.R1"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.jfas.2013.12.021"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13047-018-0303-0"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/1071100714565792"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)90606-6"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/421095"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.2106\/00004623-198062030-00017"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/501620"},{"key":"e_1_3_3_17_2","first-page":"161","article-title":"The effective period of preventive antibiotic action in experimental incisions and dermal lesions","volume":"50","author":"Burke JF","year":"1961","unstructured":"Burke JF. 1961. The effective period of preventive antibiotic action in experimental incisions and dermal lesions. Surgery 50:161\u2013168.","journal-title":"Surgery"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/17453674.2019.1577014"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.5.1441-1453.2004"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12893-020-01024-y"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-6553(99)70088-X"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.900551"},{"key":"e_1_3_3_24_2","volume-title":"Mandell, Douglas, and Bennett's principles and practice of infectious diseases","author":"Bennett JE","year":"2019","unstructured":"Bennett JE, Dolin R, BlaserMJ. 2019. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Elsevier health sciences."},{"key":"e_1_3_3_25_2","volume-title":"Antimicrobial wild type distributions of microorganisms","author":"M EUCAST","year":"2018","unstructured":"M EUCAST. 2018. Antimicrobial wild type distributions of microorganisms. European Committee on Antimicrobial Susceptibility Testing Vaxjo, Sweden."},{"key":"e_1_3_3_26_2","unstructured":"de Greeff SC Kolwijck E Schoffelen AF Verduin CM. 2022. NethMap 2022. Consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands in 2021 \/ MARAN 2022"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/421095"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/CORR.0000000000002808"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01348-13"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/s1067-2516(96)80085-8"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2015.067"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11999-011-2111-8"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2019.1621161"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.19343"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00494-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00494-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T13:02:30Z","timestamp":1720530150000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00494-24"}},"subtitle":[],"editor":[{"given":"James E.","family":"Leggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7,9]]}},"alternative-id":["10.1128\/aac.00494-24"],"URL":"https:\/\/doi.org\/10.1128\/aac.00494-24","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"2024-04-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00494-24"}}